Palbociclib, ribociclib, and abemaciclib are currently FDA-approved CDK4/6 inhibitors and are used in combination with endocrine therapies for the treatment of ER-positive/HER2-negative breast cancer [107, 108]. The gene discussed is CDK4; the disease is breast cancer.